287 related articles for article (PubMed ID: 32193227)
1. B Cells Improve Overall Survival in HPV-Associated Squamous Cell Carcinomas and Are Activated by Radiation and PD-1 Blockade.
Kim SS; Shen S; Miyauchi S; Sanders PD; Franiak-Pietryga I; Mell L; Gutkind JS; Cohen EEW; Califano JA; Sharabi AB
Clin Cancer Res; 2020 Jul; 26(13):3345-3359. PubMed ID: 32193227
[TBL] [Abstract][Full Text] [Related]
2. Programmed Death-1/Programmed Death-Ligand 1-Axis Blockade in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma Stratified by Human Papillomavirus Status: A Systematic Review and Meta-Analysis.
Xu Y; Zhu G; Maroun CA; Wu IXY; Huang D; Seiwert TY; Liu Y; Mandal R; Zhang X
Front Immunol; 2021; 12():645170. PubMed ID: 33897693
[TBL] [Abstract][Full Text] [Related]
3. HPV16 E5 Mediates Resistance to PD-L1 Blockade and Can Be Targeted with Rimantadine in Head and Neck Cancer.
Miyauchi S; Sanders PD; Guram K; Kim SS; Paolini F; Venuti A; Cohen EEW; Gutkind JS; Califano JA; Sharabi AB
Cancer Res; 2020 Feb; 80(4):732-746. PubMed ID: 31848196
[TBL] [Abstract][Full Text] [Related]
4. LCL161, a SMAC-mimetic, Preferentially Radiosensitizes Human Papillomavirus-negative Head and Neck Squamous Cell Carcinoma.
Yang L; Kumar B; Shen C; Zhao S; Blakaj D; Li T; Romito M; Teknos TN; Williams TM
Mol Cancer Ther; 2019 Jun; 18(6):1025-1035. PubMed ID: 31015310
[TBL] [Abstract][Full Text] [Related]
5. Harnessing radiotherapy-induced NK-cell activity by combining DNA damage-response inhibition and immune checkpoint blockade.
Patin EC; Dillon MT; Nenclares P; Grove L; Soliman H; Leslie I; Northcote D; Bozhanova G; Crespo-Rodriguez E; Baldock H; Whittock H; Baker G; Kyula J; Guevara J; Melcher AA; Harper J; Ghadially H; Smith S; Pedersen M; McLaughlin M; Harrington KJ
J Immunother Cancer; 2022 Mar; 10(3):. PubMed ID: 35314434
[TBL] [Abstract][Full Text] [Related]
6. Targeting interferon signaling and CTLA-4 enhance the therapeutic efficacy of anti-PD-1 immunotherapy in preclinical model of HPV
Dorta-Estremera S; Hegde VL; Slay RB; Sun R; Yanamandra AV; Nicholas C; Nookala S; Sierra G; Curran MA; Sastry KJ
J Immunother Cancer; 2019 Sep; 7(1):252. PubMed ID: 31533840
[TBL] [Abstract][Full Text] [Related]
7. Characteristics of B lymphocyte infiltration in HPV
Zhang S; Wang B; Ma F; Tong F; Yan B; Liu T; Xie H; Song L; Yu S; Wei L
Cancer Sci; 2021 Apr; 112(4):1402-1416. PubMed ID: 33529452
[TBL] [Abstract][Full Text] [Related]
8. PD-1-expressing tumor-infiltrating T cells are a favorable prognostic biomarker in HPV-associated head and neck cancer.
Badoual C; Hans S; Merillon N; Van Ryswick C; Ravel P; Benhamouda N; Levionnois E; Nizard M; Si-Mohamed A; Besnier N; Gey A; Rotem-Yehudar R; Pere H; Tran T; Guerin CL; Chauvat A; Dransart E; Alanio C; Albert S; Barry B; Sandoval F; Quintin-Colonna F; Bruneval P; Fridman WH; Lemoine FM; Oudard S; Johannes L; Olive D; Brasnu D; Tartour E
Cancer Res; 2013 Jan; 73(1):128-38. PubMed ID: 23135914
[TBL] [Abstract][Full Text] [Related]
9. Squamous Cell Carcinomas of the Head and Neck Cancer Response to Programmed Cell Death Protein-1 Targeting and Differential Expression of Immunological Markers: A Case Report.
Merhi M; Raza A; Inchakalody VP; Nashwan AJJ; Allahverdi N; Krishnankutty R; Uddin S; Zar Gul AR; Al Homsi MU; Dermime S
Front Immunol; 2018; 9():1769. PubMed ID: 30108590
[TBL] [Abstract][Full Text] [Related]
10. Peripheral blood monocyte and T-lymphocyte activation levels at diagnosis predict long-term survival in head and neck squamous cell carcinoma patients.
Aarstad HJ; Vintermyr OK; Ulvestad E; Aarstad HH; Kross KW; Heimdal JH
APMIS; 2015 Apr; 123(4):305-14. PubMed ID: 25801083
[TBL] [Abstract][Full Text] [Related]
11. Subjugation of TGFβ Signaling by Human Papilloma Virus in Head and Neck Squamous Cell Carcinoma Shifts DNA Repair from Homologous Recombination to Alternative End Joining.
Liu Q; Ma L; Jones T; Palomero L; Pujana MA; Martinez-Ruiz H; Ha PK; Murnane J; Cuartas I; Seoane J; Baumann M; Linge A; Barcellos-Hoff MH
Clin Cancer Res; 2018 Dec; 24(23):6001-6014. PubMed ID: 30087144
[TBL] [Abstract][Full Text] [Related]
12. Defining HPV-specific B cell responses in patients with head and neck cancer.
Wieland A; Patel MR; Cardenas MA; Eberhardt CS; Hudson WH; Obeng RC; Griffith CC; Wang X; Chen ZG; Kissick HT; Saba NF; Ahmed R
Nature; 2021 Sep; 597(7875):274-278. PubMed ID: 33208941
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of BIRC2 Sensitizes α7-HPV-Related Cervical Squamous Cell Carcinoma to Chemotherapy.
Lin CY; Wang CC; Wu RC; Yang LY; Chang CB; Pan YB; Chao A; Lai CH
Int J Mol Sci; 2021 Oct; 22(20):. PubMed ID: 34681681
[TBL] [Abstract][Full Text] [Related]
14. Validation and characterisation of prognostically significant PD-L1
Young RJ; Bressel M; Porceddu S; Cernelc J; Savas P; Liu H; Urban D; Thai AA; Cooper C; Fua T; Neeson P; Rischin D; Solomon B
Oral Oncol; 2020 Feb; 101():104516. PubMed ID: 31838340
[TBL] [Abstract][Full Text] [Related]
15. Impact of human papilloma virus infection on the response of head and neck cancers to anti-epidermal growth factor receptor antibody therapy.
Pogorzelski M; Ting S; Gauler TC; Breitenbuecher F; Vossebein I; Hoffarth S; Markowetz J; Lang S; Bergmann C; Brandau S; Jawad JA; Schmid KW; Schuler M; Kasper S
Cell Death Dis; 2014 Feb; 5(2):e1091. PubMed ID: 24577089
[TBL] [Abstract][Full Text] [Related]
16. Characterization of the tumor immune microenvironment in human papillomavirus-positive and -negative head and neck squamous cell carcinomas.
Succaria F; Kvistborg P; Stein JE; Engle EL; McMiller TL; Rooper LM; Thompson E; Berger AE; van den Brekel M; Zuur CL; Haanen J; Topalian SL; Taube JM
Cancer Immunol Immunother; 2021 May; 70(5):1227-1237. PubMed ID: 33125511
[TBL] [Abstract][Full Text] [Related]
17. Human Papillomavirus Regulates HER3 Expression in Head and Neck Cancer: Implications for Targeted HER3 Therapy in HPV
Brand TM; Hartmann S; Bhola NE; Peyser ND; Li H; Zeng Y; Isaacson Wechsler E; Ranall MV; Bandyopadhyay S; Duvvuri U; LaVallee TM; Jordan RCK; Johnson DE; Grandis JR
Clin Cancer Res; 2017 Jun; 23(12):3072-3083. PubMed ID: 27986750
[No Abstract] [Full Text] [Related]
18. Radioimmunotherapy of experimental head and neck squamous cell carcinoma (HNSCC) with E6-specific antibody using a novel HPV-16 positive HNSCC cell line.
Harris M; Wang XG; Jiang Z; Goldberg GL; Casadevall A; Dadachova E
Head Neck Oncol; 2011 Feb; 3(1):9. PubMed ID: 21314983
[TBL] [Abstract][Full Text] [Related]
19. Integrative and comparative genomic analysis of HPV-positive and HPV-negative head and neck squamous cell carcinomas.
Seiwert TY; Zuo Z; Keck MK; Khattri A; Pedamallu CS; Stricker T; Brown C; Pugh TJ; Stojanov P; Cho J; Lawrence MS; Getz G; Brägelmann J; DeBoer R; Weichselbaum RR; Langerman A; Portugal L; Blair E; Stenson K; Lingen MW; Cohen EE; Vokes EE; White KP; Hammerman PS
Clin Cancer Res; 2015 Feb; 21(3):632-41. PubMed ID: 25056374
[TBL] [Abstract][Full Text] [Related]
20. Comprehensive T-cell immunophenotyping and next-generation sequencing of human papillomavirus (HPV)-positive and HPV-negative head and neck squamous cell carcinomas.
Poropatich K; Fontanarosa J; Swaminathan S; Dittmann D; Chen S; Samant S; Zhang B
J Pathol; 2017 Nov; 243(3):354-365. PubMed ID: 28771750
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]